GlassScriptPhysician profile
Mark P Rubino
NPI 1285605469
$8,940.95
in general payments reported to CMS, 2019-2025
36 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $2,104 · 2021: $3,758 · 2022: $724 · 2023: $437 · 2024: $523 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,781.09 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $2,354.44 | 2020-2021 | |
| Biogen, INC. | $707.86 | 2020-2025 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $574.39 | 2019-2024 | Austedo Xr, Austedo |
| Amgen INC. | $442.75 | 2019-2022 | |
| Lilly USA, LLC | $417.80 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Eisai INC. | $221.81 | 2021-2025 | |
| Lundbeck LLC | $169.34 | 2021-2025 | Vyepti |
| Upsher-Smith Laboratories LLC | $148.89 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $124.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $113.83 | 2019-2023 | |
| Genzyme Corporation | $111.48 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $98.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $74.77 | 2022 | |
| Emd Serono, INC. | $61.41 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $47.67 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $45.48 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $40.65 | 2023 | Onpattro |
| Pfizer INC. | $39.70 | 2024-2025 | |
| Daiichi Sankyo INC. | $39.63 | 2019 | |
| Sk Life Science, INC. | $39.23 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.38 | 2022-2023 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $29.82 | 2022 | |
| Gilead Sciences, INC. | $24.70 | 2023 | Trodelvy |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Tanabe Pharma America, INC. | $18.93 | 2023 | |
| Scilex Pharmaceuticals INC. | $18.82 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $18.66 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.32 | 2019 | |
| Abbott Laboratories | $15.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.36 | 2020 | |
| Redhill Biopharma INC. | $15.03 | 2021 | |
| Almatica Pharma LLC | $14.55 | 2023 | Gralise |
| Currax Pharmaceuticals LLC | $14.28 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.02 | 2023 | Quviviq |
| Promius Pharma LLC | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rubino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.